Investigational New Drug Development
IND Development Process Overview
An academic researcher may be required to submit an IND application to FDA in order to study a marketed medical product in a new (i.e. unapproved) clinical indication. An investigator is always required to hold an IND to study an unmarketed (i.e. unapproved) medical product. In both cases, the products are considered “investigational” by FDA. The vast majority of INDs on file with the FDA are for noncommercial research.
Regulatory Consulting & Drug Development
We consult with investigators on the scientific information required to support an Investigational New Drug application to FDA.
Learn More ›
Step-by-Step Toolkit
The toolkit contains templates and guidance relevant to each step in the process. We recommend that you submit your first IND to ITHS for review prior to submission to FDA.
Learn More ›
FAQ
Read frequently asked questions about Drug Studies.
Learn More ›
Related Links
Contact Us
Contact Us
Request Services
Request Services
Please sign in below to access this form.
Access to this form is restricted to ITHS Members. Please sign in.
Not yet an ITHS member?
Members of ITHS are part of a unique catalyst that accelerates discoveries to practice. If you haven't signed up for an ITHS membership yet, learn more and join us.